Alnylam Announces Date Of Planned FDA Advisory Committee Meeting As Of September 13, 2023 For ONPATTRO For The Treatment Of The Cardiomyopathy Of ATTR Amyloidosis
Portfolio Pulse from Happy Mohamed
Alnylam Pharmaceuticals has announced that the FDA has set a date of September 13, 2023, for the meeting of the Cardiovascular and Renal Drugs Advisory Committee to review the supplemental New Drug Application for patisiran, an investigational treatment for the cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis. The FDA has set an action date of October 8, 2023, under the Prescription Drug User Fee Act.
June 30, 2023 | 1:04 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
The announcement of the FDA review date for Alnylam's new drug application for patisiran could potentially impact the company's stock in the short term. The outcome of the review could significantly affect the company's future revenues and growth.
The announcement of the FDA review date for a new drug application is a significant event for a pharmaceutical company. It signals the potential for a new revenue stream if the drug is approved. However, the outcome of the review is uncertain, hence the neutral score. The relevance is high as the news directly pertains to Alnylam. The importance is also high as the outcome could significantly affect the company's future revenues and growth.
CONFIDENCE 75
IMPORTANCE 80
RELEVANCE 100